ICRF-193

ICRF-193 is a DNA Topoisomerase II inhibitor. (S, S) - and (R, R) -isomers ICRF-193 make up an racemic mixture, ICRF-196 (HY-118590A) . ICRF-193 can inhibit DNA syntheses and induces apoptosis. ICRF-193 exhibits anti-cancer and anti-inflammation effects. ICRF-193 shows cardioprotective effect against anthracycline toxicity to cardiomyocytes. ICRF-193 can be used for the researches of cancer, infection, inflammation and cardiovascular disease, such as acute promyelocytic leukemia[1][2][3][4][5][6].

Product Specifications

CAS Number

[21416-88-6]

Product Name Alternative

AZD0865

UNSPSC

12352005

Hazard Statement

H301, H317

Target

Apoptosis; DNA/RNA Synthesis; Fungal; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/icrf-193.html

Purity

99.64

Solubility

DMSO : 2.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[C@@H]([C@@H](C)N(CC(N1)=O)CC1=O)N(CC(N2)=O)CC2=O

Molecular Formula

C12H18N4O4

Molecular Weight

282.30

Precautions

H301, H317

References & Citations

[1]Nakazawa N, et al. ICRF-193, an anticancer topoisomerase II inhibitor, induces arched telophase spindles that snap, leading to a ploidy increase in fission yeast. Genes Cells. 2016 Sep;21 (9) :978-93.|[2]Niitsu N, et al. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30 (11) :1273-82.|[3]Hossain MS, et al. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells. Genes Cells. 2002 Mar;7 (3) :285-94|[4]Brindle A, et al. The Bisdioxopiperazine ICRF-193 Attenuates LPS-induced IL-1β Secretion by Macrophages. Inflammation. 2024 Feb;47 (1) :84-98.|[5]Jirkovská A, et al. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J Med Chem. 2021 Apr 8;64 (7) :3997-4019.|[6]Tanimoto C, et al. ICRF-193 modifies etoposide-induced apoptosis in thymocytes. Acta Med Okayama. 1995 Dec;49 (6) :281-6.